F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting
F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces that new preclinical data on FS120, a mAb² product candidate targeting OX40 and CD137, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting in National Harbor, Maryland, United States, being held from 06 - 10 November 2019.
FS120 is a potentially best-in-class dual agonist that has the potential to overcome cancer resistance by simultaneously engaging OX40 (CD134, TNFRSF4) and CD137 (4-1BB), two receptors found on the surface of tumor-infiltrating lymphocytes. Targeting this class of receptors using bispecific tetravalent binding mobilizes multiple arms of the immune system, which research shows is essential for eliminating tumors. F-star’s preclinical data demonstrated that FS120’s crosslink-dependent approach has the potential to provide therapeutic benefit, for example in combination with checkpoint antagonists, and reverse T cell exhaustion in immunosuppressive tumor environments.
Neil Brewis, CSO of F-star said “Recent clinical trials involving agonist molecules have reported that a meaningful anti-cancer response is often associated with liver toxicity, in line with preclinical observations. F-star’s OX40/CD137 mAb² antibody is showing preclinical evidence that an effective tumor-killing response can be decoupled from liver inflammation. We look forward to progressing FS120 into the clinic as we aim to potentially improve treatment outcomes for patients with difficult-to-treat cancers.”
Some CD137 agonist antibodies have been shown to induce adverse effects either in clinical or in preclinical studies as they constitutively activate T cells and thus release cytotoxic immunity outside of the tumor. In contrast, FS120 is designed to mitigate off-target toxicity through conditional, crosslink-dependent activation upon binding to both OX40 and CD137, which are predominantly present on T cells in the tumor microenvironment.
F-star expects to submit an IND application for FS120 during the fourth quarter of 2019.
Details of the poster are below:
Crosslink-independent CD137 agonism is associated with liver inflammation
Abstract poster number: P775
Poster hall location: Prince George AB
Poster hall hours: 07:00 to 20:00 on Friday 08 November 2019
Poster presentation hours: 12:30 to 14:00 and 18:30 to 20:00 on Friday 08 November 2019
- ENDS -
About F-star
F-star is a clinical-stage immuno-oncology company singularly focused on transforming the lives of patients with cancer through the development of its innovative tetravalent mAb2 bispecific antibodies. With four distinct binding sites in a natural human antibody format, F-star believes its proprietary approach will overcome many of the challenges facing current immuno-oncology therapies. F-star’s vision is to transform the treatment of cancer through the development of differentiated and well-tolerated mAb2 bispecific antibodies, which are designed to simultaneously address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.
mAb2™ is a trademark of F-star.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005210/en/
Contact information
For investor enquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com
Consilium Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel: +44 (0)20 3709 5700
E-mail: F-star@consilium-comms.com
For media enquiries
Pierre Peotta
Communications Manager
+44 (0)1223 948 094
+44 (0)7392 080 279
pierre.peotta@f-star.com
US
Catherine London, US President
Tel: +1 917-763-2709
E-mail: F-star@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
With 40% of Agentic AI Projects Predicted to Fail, Leading Software Developer Says Compliance Is the One Place Where Agentic AI Will Thrive2.12.2025 02:01:00 EET | Press release
The CEO of one of the world’s leading global compliance software developers, Ideagen, has today (December 2, 2025) said compliance represents the one domain where autonomous AI will succeed – despite technology insights company Gartner® warning "… over 40% of agentic AI projects will be canceled by the end of 2027”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201511477/en/ Ben Dorks, Ideagen CEO Speaking at the launch of their own agentic AI platform Ideagen Mazlan, Ben Dorks said: “Autonomous AI will succeed in compliance because failure is measurable, stakes are high and outcomes are binary. “AI that continuously monitors jurisdictional or industry specific compliance frameworks, detects patterns across thousands of records, raises actions for others to follow, flags gaps before audits, autonomously? That's agentic. It will literally save lives and is the most transformative shift in protecting people, products and p
VeriSilicon’s NPU IP VIP9000NanoOi-FS has Achieved ISO 26262 ASIL B Certification2.12.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced that its NPU IP VIP9000NanoOi-FS has successfully achieved ISO 26262 ASIL B certification, marking a significant milestone in the functional safety capabilities of the company’s neural network processing unit portfolio. This IP features an architecture streamlined for seamless SoC integration, delivering high-quality inference with low power consumption and a compact silicon footprint. The certificate was issued by SGS-TÜV Saar, an international testing, inspection and certification institution. As part of VeriSilicon’s VIP9000 series, the VIP9000NanoOi-FS IP is designed for automotive and edge AI applications, providing high-performance neural network processing with a safety-compliant architecture. The IP supports a wide range of AI inferencing models including Large Language Models (LLMs) and Convolutional Neural Networks (CNNs), with hardware-accelerated AI inference, enabling real-time applications such as object and scene detection, augment
UMA Launches from Europe to Shape the Global Future of Physical AI2.12.2025 00:52:00 EET | Press release
UMA (Universal Mechanical Assistant), a new robotics intelligence company founded by former leaders from Tesla, Google DeepMind, Nvidia and Hugging Face, launches today with a clear goal: to bring advanced AI into the physical world and build humanoid robots ready for real work, in real environments, at scale. UMA’s founders were instrumental in shaping the last decade of breakthroughs in deep learning, robotics and open-source AI. They are convinced that the next era of artificial intelligence won’t unfold on screens, it will happen in warehouses, hospitals, labs, factories and homes, where machines must face friction, unpredictability and human complexity. UMA is built for this transition: from digital intelligence to physical autonomy. AI Is Moving Off the Screen and into the World The past ten years gave rise to generative models, multimodal systems and language-based intelligence. The next decade will be defined by robotics, powered by an AI that can see, move, manipulate and make
FlightSafety International Appoints Eric Hinson as Chief Executive Officer2.12.2025 00:00:00 EET | Press release
FlightSafety International Inc. today announced the appointment of Eric Hinson as chief executive officer, effective immediately. Hinson will succeed former president Barbara Telek who recently announced her retirement. Hinson’s appointment marks a return to FlightSafety. He served as an executive vice president from 2009 to 2012 before leaving to be the president and CEO of Simcom International, Inc. Hinson started his aviation career as a naval aviator flying tactical aircraft in training, fleet, and operational test squadrons. Today, he is an active ATP-rated pilot with more than 5,000 total flight hours. He brings a unique operational perspective to the position—one that blends executive leadership with firsthand experience. In addition to FlightSafety and Simcom, Hinson has served in a variety of senior leadership positions at leading aviation companies, including Honeywell, Gulfstream, and Piaggio Aerospace. He also served as a board member of the General Aviation Manufacturer As
Ubigi Voted Most Reliable eSIM for Mobile Professionals According to Latency Report 20251.12.2025 17:13:00 EET | Press release
Ubigi, a pioneer in eSIM solutions for travellers and connected professionals, has been ranked number one worldwide for connection quality according to the Latency Report 2025. This independent study evaluates eSIMs based on three key criteria: latency, jitter and packet loss. Thanks to its cutting-edge international network infrastructure, Ubigi has established itself as the benchmark for reliability for mobile professionals. Its architecture is based on seven Packet Gateways (P-GWs) spread across Europe, Asia and the Americas, allowing data to transit through the Internet point closest to the user. The result: latency reduced by a factor of two to five depending on the area and optimal stability for video conferencing, VPN and cloud services. Ubigi's performance, validated by the Latency Report 2025, stands out: Average latency: 35 ms in Europe, 92 ms in Asia; Jitter: only 5 ms; Packet loss: < 0.2%, one of the best reliability ratings measured. These results, confirmed by tests in Li
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom